Summary
Plasma p-tau217 testing can help detect preclinical Alzheimer disease in cognitively unimpaired adults. Using it as a first-line screen followed by positron emission tomography or cerebrospinal fluid testing boosts accuracy, reduces false positives, and streamlines recruitment.
Source: Medical News
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
